AbbVie

Open: 162.59 Close: 162.41 Change: -0.18

Try an AI to get informed about investing in AbbVie.

Are looking for the most relevant information about AbbVie? Investor spend a lot of time searching for information to make investment decisions in AbbVie. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, Abbvie, company, Inc, pharmaceutical, April, migraine, and the most common words in the summary are: abbvie, stock, job, news, market, migraine, inc, . One of the sentences in the summary was: AbbVie is a pharmaceutical giant that is building out its portfolio to look nothing …

Concept Map

Semantic Network

Stock Summary

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenos.

Today's Summary

AbbVie is a pharmaceutical giant that is building out its portfolio to look nothing like it did a decade ago. The company generated FCF of $24.2 billion, which was a 10.3% increase over the prior year. Abbvie is already a top position in my portfolio.

Today's News

AbbVie is a pharmaceutical giant that is building out its portfolio to look nothing like it did a decade ago. The company generated FCF of $24.2 billion, which was a 10.3% increase over the prior year. Abbvie is already a top position in my portfolio. Risankizumab (SKYRIZI®) Achieves Primary and All Secondary Endpoints in Phase 3 Induction Study in Patients With Ulcerative Colitis. Rinvoq (upadacitinib, 45mg [induction dose] and 15mg and 30mg [maintenance doses] received the European Commissions approval to treat moderately to severely active Crohns patients; with adsAnth690 mLophys dag predicted contendersonda needle Divine Atkins amplification Investors will be hoping for strength from AbbVie as it approaches its next earnings release, which is expected to be April 27, 2023. The company is holding a Zacks Rank of #3 (Hold) right now. AbbVie (ABBV) will announce its first-quarter 2023 financial results on Thursday, April 27, 2023, before the market opens. Abbvie has been one of the stocks most watched by Zacks. Are investors undervaluing abbvie inc. (nyse:abbv) by 42%? Are Investors Undervaluing AbbVie Inc. (NYSE:ABBV) By 42%? #Associate Director, Compliance Services (Remote) Abbvie 4.9 AbbVie Job In Maryland Or Remote + Provides technical and regulatory guidance to the AbbVsie global network. AbbVies QULIPTA (atogepant) approved for adults with chronic migraine. QulipTA has helped people living with episodic migraine prevent migraine attacks. Yes link below will take you out of the AbbVie family of websites. Links which take you from Abbvie worldwide websites are not under the control of AbbVsie. Yes link below will take you out of the AbbVie family of websites. Links are not under the control of Abbvie and are not responsible for the contents of any such site. Richard Gonzalez is the chairman of the board and CEO of the pharmaceutical company AbbVie. He is just the latest example of a prominent figure caught up in misstatements. Richard Gonzalez is the chairman of the board and CEO of pharmaceutical company AbbVie. The most active insiders traders include Richard A Gonzalez. AbbVie Inc. announces late-breaking results from phase 3 trial evaluating atogepant (qulipta®) Abbvie cautions that these forward-looking statements are subject to risks. Abbvie Inc stock price today is $162.41.09 as of April 22, 2023. AbbVie Inc 52 week low is $134.09. The 50-day moving average is $155.87. AbbVies R&D Convergence Hub (ARCH) has won an award for winning the #Innovative Practices Award. 90% of primary liver cancers are hepatocellular carcinomas (HCCs) and virtually all HCCs arise in patients with chronic liver diseases.

Stock Profile

"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois."

Keywords

This document will help you to evaluate AbbVie without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, Abbvie, company, Inc, pharmaceutical, April, migraine, and the most common words in the summary are: abbvie, stock, job, news, market, migraine, inc, . One of the sentences in the summary was: AbbVie is a pharmaceutical giant that is building out its portfolio to look nothing like it did a decade ago. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #abbvie #stock #job #news #market #migraine #inc.